Hindustan Biosciences Limited is engaged in the manufacturing and sale of pharmaceutical products.Product Portfolio: a) Tablets b) Capsules c) Eye/Ear/Nasal Drops d) Dry and Liquid Injectables e) Liquid/Dry Syrups f) Pre-Filled Syringes g) Non Sterile/Sterile Ointments
Hindustan Biosciences Ltd has announced the publication of its financial results for the quarter ended June 30, 2025. The company reported total revenue of 0.335 Cr, marking a decline from both the previous quarter and the same period last year. Net profit for the quarter stood at 0.014 Cr, significantly...
Hindustan Biosciences' board meeting approved the financial results for the first quarter ended June 30, 2025, reporting a total revenue of Rs 0.335 Cr and a profit of Rs 0.014 Cr, with an EPS of Rs 0.01. The board noted the resignation of Mr. Devanshu Ravinder Dange as Company Secretary...
Hindustan Biosciences' Board approved the financial results for the quarter, reporting a profit of 0.014 Cr on total revenue of 0.3350 Cr. The company announced the resignation of Mr. Devanshu Ravinder Dange as Company Secretary and Compliance Officer, and promptly appointed Mr. Shailendra Vyas to the role. Additionally, the Board...
Hindustan Biosciences' board has approved the financial results for the quarter ending June 30, 2025, reporting a profit of 0.014 Cr on revenue of 0.3219 Cr. The company also announced a change in its key management: Mr. Devanshu Dange resigned as Company Secretary and Compliance Officer, with Mr. Shailendra Vyas...
Hindustan Biosciences Ltd. has issued a routine compliance update on its share transfer operations for the quarter ending June 30, 2025. The company confirmed that its Registrar and Share Transfer Agent did not receive any requests for converting physical equity share certificates to electronic form (dematerialization) or vice-versa (rematerialization) during...
